European Journal of Cancer
Volume 46, Issue 2 , Pages 270-283 , January 2010

Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline

  • Claus Garbe

      Affiliations

    • Center for Dermatooncology, Department of Dermatology, Liebermeisterstr. 25, 72076 Tübingen, Germany
    • Corresponding Author InformationCorresponding author: Tel.: +49 7071 29 87110; fax: +49 7071 29 5187.
    • On behalf of the European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization for Research and Treatment of Cancer (EORTC).
    • ,
  • Ketty Peris

      Affiliations

    • University Department of Dermatology, L’Aquila, Italy
    • On behalf of the European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization for Research and Treatment of Cancer (EORTC).
    • ,
  • Axel Hauschild

      Affiliations

    • University Department of Dermatology, Kiel, Germany
    • On behalf of the European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization for Research and Treatment of Cancer (EORTC).
    • ,
  • Philippe Saiag

      Affiliations

    • University Department of Dermatology, Université de Versailles-Saint Quentin en Yvelines, APHP, Boulogne, France
    • On behalf of the European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization for Research and Treatment of Cancer (EORTC).
    • ,
  • Mark Middleton

      Affiliations

    • Department of Medical Oncology, University of Oxford, UK
    • On behalf of the European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization for Research and Treatment of Cancer (EORTC).
    • ,
  • Alain Spatz

      Affiliations

    • Gustave Roussy Institute, Villejuif, France
    • On behalf of the European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization for Research and Treatment of Cancer (EORTC).
    • ,
  • Jean-Jacques Grob

      Affiliations

    • University Department of Dermatology, Marseille, France
    • On behalf of the European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization for Research and Treatment of Cancer (EORTC).
    • ,
  • Josep Malvehy

      Affiliations

    • Melanoma Unit, Department of Dermatology, Hospital Clinic, Barcelona, Spain
    • On behalf of the European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization for Research and Treatment of Cancer (EORTC).
    • ,
  • Julia Newton-Bishop

      Affiliations

    • Section of Biostatistics and Epidemiology, Leeds Institute of Molecular Medicine, University of Leeds, UK
    • On behalf of the European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization for Research and Treatment of Cancer (EORTC).
    • ,
  • Alexander Stratigos

      Affiliations

    • 1st Department of Dermatology, University of Athens, A. Sygros Hospital, Athens, Greece
    • On behalf of the European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization for Research and Treatment of Cancer (EORTC).
    • ,
  • Hubert Pehamberger

      Affiliations

    • University Department of Dermatology, Vienna, Austria
    • On behalf of the European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization for Research and Treatment of Cancer (EORTC).
    • ,
  • Alexander Eggermont

      Affiliations

    • University Department of Surgical Oncology, Erasmus University, Rotterdam, Netherlands
    • On behalf of the European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization for Research and Treatment of Cancer (EORTC).

Received 25 October 2009 ,Accepted 29 October 2009.

References 

  1. Garbe C, Hauschild A, Volkenandt M, et al. Evidence and interdisciplinary consensus-based German guidelines: surgical treatment and radiotherapy of melanoma. Melanoma Res. 2008;18:61–67
  2. Garbe C, Hauschild A, Volkenandt M, et al. Evidence and interdisciplinary consense-based German guidelines: diagnosis and surveillance of melanoma. Melanoma Res. 2007;17:393–399
  3. Saiag P, Bosquet L, Guillot B, et al. Management of adult patients with cutaneous melanoma without distant metastasis. 2005 update of the French Standards, Options and Recommendations guidelines. Summary report. Eur J Dermatol. 2007;17:325–331
  4. Dummer R, Panizzon R, Bloch PH, et al. Updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma. Dermatology. 2005;210:39–44
  5. Roberts DL, Anstey AV, Barlow RJ, et al. U.K. guidelines for the management of cutaneous melanoma. Br J Dermatol. 2002;146:7–17
  6. Dummer R, Hauschild A, Jost L. Cutaneous malignant melanoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann. Oncol. 2008;19(Suppl. 2):ii86–ii88
  7. de Vries E, Bray FI, Coebergh JW, et al. Changing epidemiology of malignant cutaneous melanoma in Europe 1953–1997: rising trends in incidence and mortality but recent stabilizations in western Europe and decreases in Scandinavia. Int J Cancer. 2003;107:119–126
  8. Garbe C, Blum A. Epidemiology of cutaneous melanoma in Germany and worldwide. Skin Pharmacol Appl Skin Physiol. 2001;14:280–290
  9. MacKie RM, Bray CA, Hole DJ, et al. Incidence of and survival from malignant melanoma in Scotland: an epidemiological study. Lancet. 2002;360:587–591
  10. Mansson-Brahme E, Johansson H, Larsson O, et al. Trends in incidence of cutaneous malignant melanoma in a Swedish population 1976–1994. Acta Oncol. 2002;41:138–146
  11. Bauer J, Garbe C. Acquired melanocytic nevi as risk factor for melanoma development. A comprehensive review of epidemiological data. Pigment Cell Res. 2003;16:297–306
  12. Garbe C, Buttner P, Weiss J, et al. Associated factors in the prevalence of more than 50 common melanocytic nevi, atypical melanocytic nevi, and actinic lentigines: multicenter case-control study of the Central Malignant Melanoma Registry of the German Dermatological Society. J Invest Dermatol. 1994;102:700–705
  13. Grob JJ, Gouvernet J, Aymar D, et al. Count of benign melanocytic nevi as a major indicator of risk for nonfamilial nodular and superficial spreading melanoma. Cancer. 1990;66:387–395
  14. Holly EA, Kelly JW, Shpall SN, et al. Number of melanocytic nevi as a major risk factor for malignant melanoma. J Am Acad Dermatol. 1987;17:459–468
  15. Bishop JN, Harland M, Randerson-Moor J, et al. Management of familial melanoma. Lancet Oncol. 2007;8:46–54
  16. de Snoo FA, Kroon MW, Bergman W, et al. From sporadic atypical nevi to familial melanoma: risk analysis for melanoma in sporadic atypical nevus patients. J Am Acad Dermatol. 2007;56:748–752
  17. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. New Engl J Med. 2004;351:998–1012
  18. Curtin JA, Busam K, Pinkel D, et al. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol. 2006;24:4340–4346
  19. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. New Engl J Med. 2005;353:2135–2147
  20. McGovern VJ, Mihm MC, Bailly C, et al. The classification of malignant melanoma and its histologic reporting. Cancer. 1973;32:1446–1457
  21. Clark WH, From L, Bernardino EA, et al. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res. 1969;29:705–727
  22. Mihm MC, Clark WH, From L. The clinical diagnosis, classification and histogenetic concepts of the early stages of cutaneous malignant melanomas. New Engl J Med. 1971;284:1078–1082
  23. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17, 600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19:3622–3634
  24. Ruiter DJ, Spatz A, van den Oord JJ, et al. Pathologic staging of melanoma. Semin. Oncol. 2002;29:3703–3781
  25. Spatz A, Cook MG, Elder DE, et al. Interobserver reproducibility of ulceration assessment in primary cutaneous melanomas. Eur J Cancer. 2003;39:1861–1865
  26. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127:392–399
  27. Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. New Engl J Med. 2006;355:1307–1317
  28. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3635–3648
  29. Kittler H, Pehamberger H, Wolff K, et al. Diagnostic accuracy of dermoscopy. Lancet Oncol. 2002;3:159–165
  30. Kittler H, Binder M. Follow-up of melanocytic skin lesions with digital dermoscopy: risks and benefits. Arch Dermatol. 2002;138:1379
  31. Bauer J, Blum A, Strohhacker U, et al. Surveillance of patients at high risk for cutaneous malignant melanoma using digital dermoscopy. Br J Dermatol. 2005;152:87–92
  32. Garbe C, Paul A, Kohler-Späth H, et al. Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy. J Clin Oncol. 2003;21:520–529
  33. Garbe C, Leiter U, Ellwanger U, et al. Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients. Cancer. 2003;97:1737–1745
  34. Schlagenhauff B, Schittek B, Ellwanger U, et al. Significance of serum protein S100 levels in screening for melanoma metastasis: does protein S100 enable early detection of melanoma recurrence?. Melanoma Res. 2000;10:451–459
  35. Riker AI, Glass F, Perez I, et al. Cutaneous melanoma: methods of biopsy and definitive surgical excision. Dermatol Ther. 2005;18:387–393
  36. Hauschild A, Rosien F, Lischner S. Surgical standards in the primary care of melanoma patients. Onkologie. 2003;26:218–222
  37. Martin RC, Scoggins CR, Ross MI, et al. Is incisional biopsy of melanoma harmful?. Am J Surg. 2005;190:913–917
  38. Garbe C, Schadendorf D, Stolz W, et al. Short German guidelines: malignant melanoma. J Dtsch Dermatol Ges. 2008;6(Suppl. 1):S9–S14
  39. Stevenson O, Ahmed I. Lentigo maligna: prognosis and treatment options. Am J Clin Dermatol. 2005;6:151–164
  40. Mahoney MH, Joseph MG, Temple C. Topical imiquimod therapy for lentigo maligna. Ann Plast Surg. 2008;61:419–424
  41. Buettiker UV, Yawalkar NY, Braathen LR, et al. Imiquimod treatment of lentigo maligna: an open-label study of 34 primary lesions in 32 patients. Arch Dermatol. 2008;144:943–945
  42. Cotter MA, McKenna JK, Bowen GM. Treatment of lentigo maligna with imiquimod before staged excision. Dermatol Surg. 2008;34:147–151
  43. Temple CL, Arlette JP. Mohs micrographic surgery in the treatment of lentigo maligna and melanoma. J Surg Oncol. 2006;94:287–292
  44. Breuninger H, Schlagenhauff B, Stroebel W, et al. Patterns of local horizontal spread of melanomas: consequences for surgery and histopathologic investigation. Am J Surg Pathol. 1999;23:1493–1498
  45. Thompson JF, Shaw HM. Sentinel node mapping for melanoma: results of trials and current applications. Surg Oncol Clin N Am. 2007;16:35–54
  46. Morton DL, Wanek L, Nizze JA, et al. Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes. Analysis of prognostic factors in 1134 patients from the John Wayne Cancer Clinic. Ann Surg. 1991;214:491–499
  47. Lienard D, Eggermont AM, Koops HS, et al. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study. Melanoma Res. 1999;9:491–502
  48. Blazer DG, Sondak VK, Sabel MS. Surgical therapy of cutaneous melanoma. Semin Oncol. 2007;34:270–280
  49. Tomov T, Siegel R, Bembenek A. Long-term survival in stage IV melanoma after repetitive surgical therapy. Onkologie. 2008;31:259–261
  50. Moschos SJ, Edington HD, Land SR, et al. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol. 2006;24:3164–3171
  51. Burmeister BH, Mark SB, Burmeister E, et al. A prospective phase II study of adjuvant postoperative radiation therapy following nodal surgery in malignant melanoma-Trans Tasman Radiation Oncology Group (TROG) Study 96.06. Radiother Oncol. 2006;81:136–142
  52. Olivier KR, Schild SE, Morris CG, et al. A higher radiotherapy dose is associated with more durable palliation and longer survival in patients with metastatic melanoma. Cancer. 2007;110:1791–1795
  53. Overgaard J, Gonzalez GD, Hulshof MC, et al. Hyperthermia as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma. A multicentre randomized trial by the European Society for Hyperthermic Oncology. Int J Hyperthermia. 1996;12:3–20
  54. Katz HR. The results of different fractionation schemes in the palliative irradiation of metastatic melanoma. Int J Radiat Oncol Biol Phys. 1981;7:907–911
  55. Kirova YM, Chen J, Rabarijaona LI, et al. Radiotherapy as palliative treatment for metastatic melanoma. Melanoma Res. 1999;9:611–613
  56. Konefal JB, Emami B, Pilepich MV. Analysis of dose fractionation in the palliation of metastases from malignant melanoma. Cancer. 1988;61:243–246
  57. Rate WR, Solin LJ, Turrisi AT. Palliative radiotherapy for metastatic malignant melanoma: brain metastases, bone metastases, and spinal cord compression. Int J Radiat Oncol Biol Phys. 1988;15:859–864
  58. Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004;363:1665–1672
  59. Patchell RA, Tibbs PA, Regine WF, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA. 1998;280:1485–1489
  60. Gaudy-Marqueste C, Regis JM, Muracciole X, et al. Gamma-Knife radiosurgery in the management of melanoma patients with brain metastases: a series of 106 patients without whole-brain radiotherapy. Int J Radiat Oncol Biol Phys. 2006;65:809–816
  61. Kased N, Huang K, Nakamura JL, et al. Gamma knife radiosurgery for brainstem metastases: the UCSF experience. J Neurooncol. 2008;86:195–205
  62. Lawson DH. Choices in adjuvant therapy of melanoma. Cancer Control. 2005;12:236–241
  63. Sabel MS, Sondak VK. Pros and cons of adjuvant interferon in the treatment of melanoma. Oncologist. 2003;8:451–458
  64. Shah GD, Chapman PB. Adjuvant therapy of melanoma. Cancer J. 2007;13:217–222
  65. Hauschild A, Gogas H, Tarhini A, et al. Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion. Cancer. 2008;112:982–994
  66. Garbe C, Hauschild A, Volkenandt M, et al. Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting. Melanoma Res. 2008;18:152–160
  67. Koops HS, Vaglini M, Suciu S, et al. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593. J Clin Oncol. 1998;16:2906–2912
  68. Garbe C, Eigentler TK. Diagnosis and treatment of cutaneous melanoma: state of the art 2006. Melanoma Res. 2007;17:117–127
  69. Grob JJ, Dreno B, De la SP, et al. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet. 1998;351:1905–1910
  70. Pehamberger H, Soyer HP, Steiner A, et al. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol. 1998;16:1425–1429
  71. Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996;14:7–17
  72. Kirkwood JM, Ibrahim JG, Sondak VK, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol. 2000;18:2444–2458
  73. Garbe C, Radny P, Linse R, et al. Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis. Ann Oncol. 2008;19:1195–1201
  74. Cameron DA, Cornbleet MC, MacKie RM, et al. Adjuvant interferon alpha 2b in high risk melanoma – the Scottish study. Br J Cancer. 2001;84:1146–1149
  75. Cascinelli N, Belli F, MacKie RM, et al. Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. Lancet. 2001;358:866–869
  76. Creagan ET, Dalton RJ, Ahmann DL, et al. Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol. 1995;13:2776–2783
  77. Eggermont AM, Suciu S, MacKie R, et al. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet. 2005;366:1189–1196
  78. Hancock BW, Wheatley K, Harris S, et al. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study–United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma. J Clin Oncol. 2004;22:53–61
  79. Eggermont AM, Suciu S, Santinami M, et al. Adjuvant therapy with pegylated interferon á-2b versus observation in resected stage III melanoma: Final results of EORTC 18991, a randomised phase 3 trial. Lancet. 2008;372:117–126
  80. Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000;18:158–166
  81. Schadendorf D. Is there a standard for the palliative treatment of melanoma?. Onkologie. 2002;25:74–76
  82. Ringborg U, Rudenstam CM, Hansson J, et al. Dacarbazine versus dacarbazine-vindesine in disseminated malignant melanoma: a randomized phase II study. Med Oncol Tumor Pharmacother. 1989;6:285–289
  83. Chiarion Sileni V, Nortilli R, Aversa SM, et al. Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients. Melanoma Res. 2001;11:189–196
  84. Young AM, Marsden J, Goodman A, et al. Prospective randomized comparison of dacarbazine (DTIC) versus DTIC plus interferon-alpha (IFN-alpha) in metastatic melanoma. Clin Oncol (R Coll Radiol). 2001;13:458–465
  85. Bleehen NM, Newlands ES, Lee SM, et al. Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol. 1995;13:910–913
  86. Jacquillat C, Khayat D, Banzet P, et al. Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer. 1990;66:1873–1878
  87. Mornex F, Thomas L, Mohr P, et al. A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma. Melanoma Res. 2003;13:97–103
  88. Carmichael J, Atkinson RJ, Calman KC, et al. A multicentre phase II trial of vindesine in malignant melanoma. Eur J Cancer Clin Oncol. 1982;18:1293–1295
  89. Nelimark RA, Peterson BA, Vosika GJ, et al. Vindesine for metastatic malignant melanoma. A phase II trial. Am J Clin Oncol. 1983;6:561–564
  90. Miller RL, Steis RG, Clark JW, et al. Randomized trial of recombinant alpha 2b-interferon with or without indomethacin in patients with metastatic malignant melanoma. Cancer Res. 1989;49:1871–1876
  91. Robinson WA, Mughal TI, Thomas MR, et al. Treatment of metastatic malignant melanoma with recombinant interferon alpha 2. Immunobiology. 1986;172:275–282
  92. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17:2105–2116
  93. Dorval T, Mathiot C, Chosidow O, et al. IL-2 phase II trial in metastatic melanoma: analysis of clinical and immunological parameters. Biotechnol Ther. 1992;3:63–79
  94. Legha SS, Gianan MA, Plager C, et al. Evaluation of interleukin-2 administered by continuous infusion in patients with metastatic melanoma. Cancer. 1996;77:89–96
  95. Eigentler TK, Caroli UM, Radny P, et al. Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol. 2003;4:748–759
  96. Nashan D, Muller ML, Grabbe S, et al. Systemic therapy of disseminated malignant melanoma: an evidence-based overview of the state-of-the-art in daily routine. J Eur Acad Dermatol Venereol. 2007;21:1305–1318
  97. Bajetta E, Di Leo A, Zampino MG, et al. Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma. J Clin Oncol. 1994;12:806–811
  98. Falkson CI, Ibrahim J, Kirkwood JM, et al. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol. 1998;16:1743–1751
  99. Kaufmann R, Spieth K, Leiter U, et al. Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group. J Clin Oncol. 2005;23:9001–9007
  100. Smith KA, Green JA, Eccles JM. Interferon alpha 2a and vindesine in the treatment of advanced malignant melanoma. Eur J Cancer. 1992;28:438–441
  101. Carter RD, Krementz ET, Hill GJ, et al. DTIC (nsc-45388) and combination therapy for melanoma. I. Studies with DTIC, BCNU (NSC-409962), CCNU (NSC-79037), vincristine (NSC-67574), and hydroxyurea (NSC-32065). Cancer Treat Rep. 1976;60:601–609
  102. Costanzi JJ, Al Sarraf M, Groppe C, et al. Combination chemotherapy plus BCG in the treatment of disseminated malignant melanoma: a Southwest Oncology Group Study. Med Pediatr Oncol. 1982;10:251–258
  103. Seigler HF, Lucas VS, Pickett NJ, et al. DTIC, CCNU, bleomycin and vincristine (BOLD) in metastatic melanoma. Cancer. 1980;46:2346–2348
  104. York RM, Foltz AT. Bleomycin, vincristine, lomustine, and DTIC chemotherapy for metastatic melanoma. Cancer. 1988;61:2183–2186
  105. Gundersen S. Dacarbazine, vindesine, and cisplatin combination chemotherapy in advanced malignant melanoma: a phase II study. Cancer Treat Rep. 1987;71:997–999
  106. Jungnelius U, Ringborg U, Aamdal S, et al. Dacarbazine–vindesine versus dacarbazine–vindesine–cisplatin in disseminated malignant melanoma. A randomised phase III trial. Eur J Cancer. 1998;34:1368–1374
  107. Pectasides D, Alevizakos N, Bafaloukos D, et al. Adjuvant chemotherapy with dacarbazine, vindesine, and cisplatin in pathological stage II malignant melanoma. Am J Clin Oncol. 1994;17:55–59
  108. Verschraegen CF, Kleeberg UR, Mulder J, et al. Combination of cisplatin, vindesine and dacarbazine in advanced malignant melanoma. Cancer. 1988;62:1061–1065
  109. Chapman PB, Einhorn LH, Meyers ML, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol. 1999;17:2745–2751
  110. Creagan ET, Suman VJ, Dalton RJ, et al. Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma. J Clin Oncol. 1999;17:1884–1890
  111. McClay EF, Mastrangelo MJ, Bellet RE, et al. Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma. Cancer Treat Rep. 1987;71:465–469
  112. Rao RD, Holtan SG, Ingle JN, et al. Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma. Cancer. 2006;106:375–382
  113. Egerer G, Lehnert T, Max R, et al. Pilot study of hepatic intraarterial fotemustine chemotherapy for liver metastases from uveal melanoma: a single-center experience with seven patients. Int J Clin Oncol. 2001;6:25–28
  114. Leyvraz S, Spataro V, Bauer J, et al. Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy. J Clin Oncol. 1997;15:2589–2595
  115. Siegel R, Hauschild A, Kettelhack C, et al. Hepatic arterial Fotemustine chemotherapy in patients with liver metastases from cutaneous melanoma is as effective as in ocular melanoma. Eur J Surg Oncol. 2007;33:627–632
  116. Pfohler C, Cree IA, Ugurel S, et al. Treosulfan and gemcitabine in metastatic uveal melanoma patients: results of a multicenter feasibility study. Anticancer Drugs. 2003;14:337–340
  117. Hofmann U, Szedlak M, Rittgen W, et al. Primary staging and follow-up in melanoma patients–monocenter evaluation of methods, costs and patient survival. Br J Cancer. 2002;87:151–157

PII: S0959-8049(09)00819-3

doi: 10.1016/j.ejca.2009.10.032

European Journal of Cancer
Volume 46, Issue 2 , Pages 270-283 , January 2010

Article Tools